Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Non-muscle-invasive bladder cancer

- PMLiVE

EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine

Safety committee finds possible link to ‘very rare cases’ of unusual blood blots with low blood platelets

- PMLiVE

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Decision follows mixed results from the phase 3 ACIS study

- PMLiVE

J&J delays EU COVID-19 vaccine rollout following pause in the US

FDA and CDC recommended pausing rollout in US after reported cases of rare blood clots in vaccinated individuals

- PMLiVE

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

An advisory committee to the CDC recommended extending the pause in the US to review additional data

- PMLiVE

Sanofi pays $160m upfront to acquire Tidal Therapeutics

French pharma company's acquisition of pre-clinical stage biotech includes mRNA-based research platform

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval

CHMP issues a positive opinion for S1P1 modulator based on positive phase 3 results

- PMLiVE

J&J’s MS drug ponesimod receives approval in the US

US regulator has approved the drug – now named Ponvory – for relapsing forms of MS

- PMLiVE

WHO backs emergency use of J&J’s one-dose COVID-19 vaccine

Vaccine is already approved for emergency use by the European Commission and the FDA

- PMLiVE

FDA advisory committee to review oncology accelerated approvals

Review comes after voluntary indication withdrawals for a number of cancer therapies

- PMLiVE

J&J’s one-dose COVID-19 vaccine granted EU authorisation

Company aiming to begin vaccine delivery to EU in the second half of April

Alternative Approaches to Personalized Medicine in Oncology

Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links